SPARC reports positive results from Phase 3 trial for its investigational ophthalmic suspension
Capital MarketSun Pharma Advanced Research Company today reported positive top-line results from its Phase 3 trial (CLR_16_33) for its investigational drug, PDP-716 ophthalmic suspension, for the treatment of Open Angle Glaucoma or Ocular Hypertension. The trial met its pre-specified primary endpoint, demonstrating that PDP-716 dosed once daily is equivalent to Alphagan P 0.1% dosed 3 times a day.
PDP-716 is a novel, once daily, ophthalmic suspension of Brimonidine Tartrate 0.35%. PDP-716 is developed using SPARC's proprietary TearActTM technology.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
